Calamos Advisors LLC Sells 39,605 Shares of GeneDx Holdings Corp. $WGS

Calamos Advisors LLC reduced its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 84.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,281 shares of the company’s stock after selling 39,605 shares during the period. Calamos Advisors LLC’s holdings in GeneDx were worth $468,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new stake in shares of GeneDx during the fourth quarter valued at approximately $27,000. Fifth Third Bancorp bought a new stake in shares of GeneDx during the 1st quarter worth approximately $31,000. Quarry LP boosted its stake in shares of GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares during the period. Ramirez Asset Management Inc. bought a new position in GeneDx in the 4th quarter worth about $33,000. Finally, Greenline Wealth Management LLC bought a new position in GeneDx during the 4th quarter worth about $33,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $63.48 on Friday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The company’s 50-day moving average price is $56.56 and its 200 day moving average price is $74.83. GeneDx Holdings Corp. has a 52 week low of $32.21 and a 52 week high of $170.87. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -23.69 and a beta of 1.90.

GeneDx (NASDAQ:WGS) last posted its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period in the previous year, the company posted ($0.23) EPS. As a group, research analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GeneDx news, CFO Kevin Feeley sold 3,729 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a total transaction of $226,611.33. Following the transaction, the chief financial officer owned 39,954 shares of the company’s stock, valued at $2,428,004.58. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total transaction of $638,145.77. Following the sale, the chief executive officer owned 104,372 shares of the company’s stock, valued at approximately $6,342,686.44. This represents a 9.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders acquired 2,256,420 shares of company stock worth $93,144,340 and sold 21,699 shares worth $1,295,646. Company insiders own 25.17% of the company’s stock.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Several firms, including Kahn Swick & Foti, Faruqi & Faruqi, Rosen, Hagens Berman, Robbins Geller, and others, reminded investors that the deadline to seek lead-plaintiff status in the GeneDx securities class action is August 3, 2026. Article Title
• Neutral Sentiment: Hagens Berman said it is investigating allegations that GeneDx and executives misled investors about the Fabric Genomics acquisition and expected synergies, citing the company’s sharp stock decline after its Q1 2026 results and a $31.2 million impairment charge. Article Title
• Neutral Sentiment: GeneDx also announced it will report second-quarter 2026 financial results on August 3, giving investors a near-term catalyst for the stock beyond the litigation headlines. Article Title

Analysts Set New Price Targets

WGS has been the subject of a number of research analyst reports. Piper Sandler restated an “overweight” rating and issued a $63.00 target price (up from $50.00) on shares of GeneDx in a research note on Tuesday, June 23rd. Zacks Research cut GeneDx from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Canaccord Genuity Group set a $75.00 price target on shares of GeneDx and gave the company a “buy” rating in a research note on Tuesday, May 5th. TD Cowen reaffirmed a “buy” rating on shares of GeneDx in a report on Wednesday. Finally, Craig Hallum restated a “buy” rating and issued a $85.00 target price on shares of GeneDx in a report on Tuesday, May 5th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and a consensus target price of $87.43.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.